Background: The present study aimed to evaluate the inhibitory capability of 10 pyrazole-usnic acid derivatives against dengue virus serotype 2 (DENV-2) NS2B/NS3 serine protease. The crystallographic structure model of the protease enzyme (PDB code: 2FOM) was used to conduct molecular docking studies of pyrazole-usnic acid derivatives with target proteins. Computational analysis was performed using the Molecular Operating Environment program, Gaussian View software, and ADMETLab platform. Materials and methods: The inhibitory potential of the derivatives was tested by molecular docking using panduratin A as the positive control, together with density functional theory, molecular electrostatic potential analysis, drug-likeness assessment, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling. Results: Among the tested derivatives, compounds 5 and 6 exhibited the most promising inhibitory effects against DENV-2 NS2B/NS3 serine protease. The binding free energy values for these compounds were -7.320 and -7.477 kcal/mol, respectively. These two compounds shared multiple amino acid residues with panduratin A, which was used as a reference inhibitor. Compounds 5 and 6 also displayed negative electrostatic regions surrounding their oxygen atoms, with gap energies of 0.133 and 0.137 eV and dipole moment values of 3.237 and 2.806 D, respectively. Conclusions: These computational findings suggest that compounds 5 and 6 may serve as preliminary candidates for dengue virus inhibition. However, further clinical and experimental studies are required to confirm their efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Frimayanti et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: